Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Albert Luderer, Tim Hall

Premium

BioNano Genomics has elected Albert Luderer to its board of directors. He is currently CEO and director of Integrated Diagnostics, a personalized diagnostics company. Previously, he was president and CEO of BioTrove, which was acquired by Life Technologies. He has also served as CEO of therapeutics company Light Sciences, president and chief operating officer of BioMérieux, and has held senior management positions at Dianon Systems, Boehringer Mannheim, and Corning. He holds a PhD from Rutgers University.



Oxford Gene Technologies
has appointed Tim Hall as finance director, beginning in 2012. Previously, he was director of strategic planning at Medeva, chief financial officer at Celltech Pharmaceuticals, and most recently, finance director of Lombard Medical Technologies. He holds a degree in business administration from the University of Bath and qualified as an accountant with Touche Ross.
The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.